Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia
| Autor: | Al Harbi Tj, Tourkmani Am, Ebeid Ya, Bushnag Ra, Bin Rsheed Am, Albarkah Ya |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases type 2 diabetes mellitus lcsh:Medicine 030209 endocrinology & metabolism Type 2 diabetes Hypoglycemia 03 medical and health sciences 0302 clinical medicine Glycemic control Internal medicine Diabetes mellitus medicine 030212 general & internal medicine Glycemic liraglutide Liraglutide business.industry lcsh:R Type 2 Diabetes Mellitus nutritional and metabolic diseases weight medicine.disease hypoglycemia Cohort Original Article business medicine.drug Cohort study |
| Zdroj: | Journal of Family Medicine and Primary Care Journal of Family Medicine and Primary Care, Vol 8, Iss 6, Pp 1919-1924 (2019) |
| ISSN: | 2249-4863 |
| Popis: | Context: Available therapies for type 2 diabetes mellitus (T2DM) do not adequately control glycemia in the long term as they do not address the issue of declining beta cell function and do not impact positively on weight or cardiovascular concerns associated with the disease. Aims: To measure changes in hemoglobin A1c, weight, and hypoglycemia after the addition of liraglutide to 3 therapeutic regimens of patients with T2DM. Settings and Design: An observational cohort study that was implemented in Al-Wazarat Health Center in Riyadh, Saudi Arabia. Methods and Materials: The study included 38 T2DM patients who were screened for initiation of liraglutide in combination with their treatment regimens; sulphonylurea, sulphonylurea with basal insulin (glargine), and multiple daily injections of insulin. The cohort was followed for 12 months, and the liraglutide was started with 0.6 mg dose that escalated to 1.2 and 1.8 mg. Glycemic level and weight were measured 3 times, whereas hypoglycemia was measured 2 times. Statistical Analysis Used: Quantitative continuous paired data were compared using a paired t-test and the nonparametric Wilcoxon signed rank test. Results: There was a statistically significant reduction of hemoglobin A1c with 1.2 mg dose (mean difference = 0.84%, P = 0.003). There were no statistically significant differences regarding the effect of liraglutide in addition to the 3 treatment regimens on patients' weight (P = 0.08, 0.472, 0.08, respectively). Regarding hypoglycemia, liraglutide has showed minimal effect. Conclusions: Sustained effect of liraglutide on glycemic control in patients with T2DM without any major hypoglycemic episodes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|